SINGAPORE, Oct. 02, 2025 — (NASDAQ: GDTC) – CytoMed Therapeutics, a Singaporean biopharmaceutical company in the clinical stage, is pleased to announce the publication of a preclinical study in a research article entitled “Donor-Derived Vγ9Vδ2 T Cells for Acute Myeloid Leukemia: A Promising “off-the-shelf” Immunotherapy Approach”. The company focuses on using its technologies to develop cell-based immunotherapies from donors to treat various cancers, including blood and solid tumors. The study, a collaboration with The University of Texas, MD Anderson Cancer Center (MDACC), suggests the potential of CytoMed’s allogeneic γδ T cell therapy (CTM-GDT) for treating acute myeloid leukemia (AML). This collaboration with MDACC stems from a research agreement announced in May 2023. The research article is available online.
Dr. Zeng Jieming, M.D., Ph.D., Chief Scientific and Medical Officer of CytoMed and co-author of the paper, stated that these findings justify further clinical study of allogeneic donor-derived γδ T cells in treating AML and other cancers. He added that it will help advance their next γδ T cell-based product into clinical trials after their leading product, CAR-γδ T cells (CTM-N2D), which is currently in a Phase 1 clinical trial in Singapore.
Mr. Peter Choo, Chairman of CytoMed, commented that the research provides more evidence for using allogeneic γδ T cells to treat hematologic malignancies. He added that they plan to move into clinical trials in Southeast Asia to bring new immunotherapy options to patients with limited treatment alternatives.
About CytoMed Therapeutics Limited (CytoMed)
CytoMed, established in 2018, originated from the Agency for Science, Technology and Research (A*STAR), Singapore’s leading public sector research and development agency. CytoMed is a clinical-stage biopharmaceutical company dedicated to creating innovative cell-based allogeneic immunotherapies for various human cancers, utilizing its licensed technologies: gamma delta T cell and iPSC-derived gamma delta Natural Killer T cell. The development of new technologies has been inspired by the success of existing CAR-T therapies in treating blood cancers, as well as the current limitations and commercial challenges in applying the CAR-T principle to solid tumors. For more information, please visit and follow us on Twitter (“X”) , on , and .
Forward-Looking Statements
This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. These statements involve plans, objectives, goals, strategies, future events or performance, and underlying assumptions, and other statements that are not statements of historical facts. The use of words such as “may,” “will,” “intend,” “should,” “believe,” “expect,” “anticipate,” “project,” “estimate,” or similar expressions indicates forward-looking statements. These statements are not guarantees of future performance and involve risks and uncertainties that may cause actual results to differ materially from expectations. These risks and uncertainties include, but are not limited to: the Company’s plans to develop and commercialize its product candidates; the initiation, timing, progress, and results of current and future pre-clinical studies and clinical trials and R&D programs; estimates regarding expenses, future revenue, capital requirements, and needs for additional financing; the ability to successfully acquire or obtain licenses for additional product candidates on reasonable terms; the ability to establish and maintain collaborations and/or obtain additional funding and assumptions underlying or related to any of the foregoing and other risks contained in reports filed with the SEC. Investors are cautioned not to place undue reliance on these statements, which are subject to additional factors discussed in the Company’s filings with the SEC, available at www.sec.gov. The Company does not undertake any obligation to revise these forward-looking statements to reflect events or circumstances after the date of this release.
Contact:
CytoMed Therapeutics Limited
enquiry@cytomed.sg
Attention: Evelyn Tan, Chief Corporate Officer
